Advanced Drug Delivery Systems: Technologies and Global MarketsSTUDY OBJECTIVESBCC’s goal in conducting this study is to p...
SCOPE OF THE STUDYThis study encompasses the major types of drug delivery systems used in the healthindustry. BCC analyzes...
RELATED BCC REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: SUMMARYTable 0 : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THRO...
TRANSMUCOSAL DRUG DELIVERY SYSTEMSChapter- 7: DEMAND AND USEOVERALL DRUG DELIVERY MARKETFACTORS AFFECTING THE DRUG DELIVER...
INFLAMMATORY DISEASES AND ALLERGYOPHTHALMOLOGYVIRAL AND BACTERIAL DISEASESHORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY...
GILEAD SCIENCES, INC.GLAXOSMITHKLINE PLCIMCLONE SYSTEMSJOHNSON AND JOHNSONKING PHARMACEUTICALSK.V. PHARMACEUTICAL CO.LAVIP...
Table 19 : MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGESTable 20 : PEGYLATION, ADVANTAGES AND DISADVANTAGESTable 21 ...
SYSTEMS, 2008Table 55 : SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERYSYSTEMS, 2008Table 56 : SHARES OF MANUFA...
Table 97 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH2014Table 98 : GLOBAL SALES OF DRUG DELIVERY S...
Figure 17 : SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008Figure 18 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS...
Figure 54 : NUMBER OF PATENTS BY COMPANY, 2005-2009Figure 55 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009Latest Market Resea...
Upcoming SlideShare
Loading in...5
×

ReportsnReports - Advanced Drug Delivery Systems: Technologies and Global Markets

870

Published on

BCC’s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for advanced drug delivery systems and its future direction, with an emphasis on newer techniques and products. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drug delivery systems, including the use of these products in therapeutic markets.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
870
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
21
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ReportsnReports - Advanced Drug Delivery Systems: Technologies and Global Markets

  1. 1. Advanced Drug Delivery Systems: Technologies and Global MarketsSTUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and potentialaspects of the global market for advanced drug delivery systems and its future direction,with an emphasis on newer techniques and products. The report determines the market sizeand market leaders, provides a market overview, and examines factors affecting themarkets for drug delivery systems, including the use of these products in therapeuticmarkets.An overview of types of drug delivery systems is also examined along with sales figuresover the 5 year period from 2009 to 2014. This study provides an overview of the drugdelivery market, which BCC projects will grow at a compound annual growth rate (CAGR) of7.2% over the forecast period 2009 through 2014.The study presents market size and future trends, profiles market leaders, and analyzesfactors affecting drug delivery markets and important products. The report also examinesfuture trends in drug delivery technology, the basic principles underlying different systems,and their applications. Companies manufacturing and selling the drug delivery products arealso profiled. Revenues have been broken down by the type of drug delivery systems andby different regions.Our key objective is to present a comprehensive analysis of the current market and thefuture direction of the advanced drug delivery systems.REASONS FOR DOING THIS STUDYThe drug delivery market is changing drastically due to the introduction of new techniquesand routes of delivery. R&D spending, along with increasing competition, patent expiries,new technologies, an international marketplace, and a changing customer base, is creatinga new kind of market for drug delivery systems. This study looks at almost all the systemsaffected by these factors.This is a very complex market, where many technologies are combined together to producea better delivery system, thus creating niche markets with very specialized applications.The use of liposomes, polymers, etc. in the sustained-release oral/injectable drug deliverymarket is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes aresignificant new markets.Acquisition strategies and collaborations by companies are also covered in this report, forexample, the acquisition of the Pulmonary Division of Nektar Therapeutics by Novartis. Thisstudy also discusses the strength and weaknesses of drug development market in light ofthe new technologies, growing competition, and changing customer needs.INTENDED AUDIENCEThe report consolidates much of the information on new products and new technologies inthe drug delivery industry. The study contributes to understanding market growth anddecline in drug delivery market from the point of view of the manufacturer and user. Thisstudy will be of interest to manufacturers and end-users in the pharmaceutical andbiotechnology industries, and to companies involved in R&D for drug delivery systems andnew drugs.
  2. 2. SCOPE OF THE STUDYThis study encompasses the major types of drug delivery systems used in the healthindustry. BCC analyzes each technology and looks at the manufacturers, their newproducts, sales estimates, market projections, and some market share information. BCCanalyzes the industry on a worldwide basis. Patents for drug delivery technologies are alsostudied by year, country, and assignee. The Food and Drug Administration (FDA) approvalsfor the past 5 years have been covered. New developments in this field have beenexamined in detail, including those that comprise a part of individual company profiles.METHODOLOGYBoth primary and secondary research methods were used in this report. A comprehensivesearch of the literature was conducted. The literature included technical newsletters andjournals as well as many other sources. The data were collected through interviews andcorrespondence with various pharmaceutical/ biotechnical experts. Projections were basedon estimates such as the current number of end users, potential end users, likely unitprices, rates of consumption, and market trends.INFORMATION SOURCESBCC surveyed many companies to obtain data for this study. We gathered the data fromthese industries, spoke with officials, and consulted newsletters, company literature,product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustiveinvestigations of databases by key terminology were done. In addition, we compiled datafrom current financial and trade information and government sources.ABOUT THE AUTHORShalini Shahani Dewan holds a Masters Degree in pharmaceutical chemistry. Among theresearch topics she has covered are studies on compounds of potential pharmaceuticalinterest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal bythe prime minister of India for her work and has worked with top companies in India and inthe U.S. Some of her other reports with BCC are: Reagents of Chromatography;Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems; Orthopedic Drugs,Implants and Devices; Imaging Reagents; Contract Manufacturing, Research andPackaging; The Dynamic Media, Sera and Reagent Market in Biotechnology;Opportunities inChiral Technology;Behavioral and Emotional Disorders in Children and Adolescents; andPharmaceutical Regulatory Industry; and many more.Table Of ContentsChapter- 1: INTRODUCTION – ComplimentarySTUDY OBJECTIVESREASONS FOR DOING THIS STUDYINTENDED AUDIENCESCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHOR
  3. 3. RELATED BCC REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: SUMMARYTable 0 : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014Figure 0 : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014Chapter- 3: OVERVIEWDEFINITIONSCLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATIONCLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGYChapter- 4: REGULATORY ISSUESTable 21 : FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMSTable 22 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACHYEAR, 2005- FEB. 2009Figure 1 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACHYEAR, 2005 TO FEB. 2009Table 23 : APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHERAGENCIESTable 24 : RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMSChapter- 5: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERYTYPESUSTAINED-RELEASE ORAL DOSAGE FORMSSUSTAINED-RELEASE INJECTABLE DOSAGE FORMSSUSTAINED-RELEASE TOPICAL DOSAGE FORMSPRODRUGSIMPLANTS AND IUDSTRANSDERMAL DRUG DELIVERY SYSTEMSLIPOSOMESNANOPARTICLESPOLYMERSMONOCLONAL ANTIBODIESPEGYNOLOGYBUCCAL DRUG DELIVERY SYSTEMSRECTAL DRUG DELIVERY SYSTEMSVAGINAL DRUG DELIVERY SYSTEMSOCULAR DRUG DELIVERY SYSTEMSINHALATION SYSTEMSTable 40 : MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMSChapter- 6: INDUSTRY STRUCTURESUSTAINED-RELEASE DOSAGE FORMSPRODRUGSIMPLANTS AND IUDSTRANSDERMAL DRUG DELIVERY SYSTEMSTARGETED DRUG DELIVERY SYSTEMS
  4. 4. TRANSMUCOSAL DRUG DELIVERY SYSTEMSChapter- 7: DEMAND AND USEOVERALL DRUG DELIVERY MARKETFACTORS AFFECTING THE DRUG DELIVERY TECHNOLOGY MARKETChapter- 8: MARKET ANALYSISSUSTAINED-RELEASE ORAL DOSAGE FORMSSUSTAINED-RELEASE INJECTABLE DOSGAE FORMSUSTAINED-RELEASE TOPICAL DOSAGE FORMSPRODRUGSIMPLANTS AND IUDSTRANSDERMAL DRUG DELIVERYLIPOSOMES DRUG DELIVERYNANOPARTICLESPOLYMERSPEGYLATED DRUG DELIVERYMONOCLONAL ANTIBODIESBUCCAL DRUG DELIVERYRECTAL DRUG DELIVERYOCULAR DRUG DELIVERYVAGINAL DRUG DELIVERYINHALATION DRUG DELIVERYChapter- 9: NEW DEVELOPMENTSTable 77 : DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMSTable 78 : DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMSTable 79 : DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMSTable 80 : DEVELOPMENTS IN PRODRUGSTable 81 : DEVELOPMENTS IN IMPLANTS AND IUDSTable 82 : DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMSTable 83 : DEVELOPMENTS IN LIPOSOMAL DELIVERYTable 84 : DEVELOPMENTS IN PEGYLATED DRUG DELIVERYTable 85 : DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERYTable 86 : DEVELOPMENTS IN MONOCLONAL ANTIBODIESTable 87 : DEVELOPMENTS IN BUCCAL DRUG DELIVERYTable 88 : DEVELOPMENTS IN VAGINAL DRUG DELIVERYTable 89 : DEVELOPMENTS IN RECTAL DRUG DELIVERYChapter- 10: MARKET BY THERAPEUTIC AREASMARKET SIZEMARKET SHARECARDIOVASCULAR DISEASESONCOLOGYGASTROINTESTINALUROLOGYDIABETESCENTRAL NERVOUS SYSTEM DISORDERRESPIRATORY DRUG DELIVERY SYSTEMS
  5. 5. INFLAMMATORY DISEASES AND ALLERGYOPHTHALMOLOGYVIRAL AND BACTERIAL DISEASESHORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGYOTHERSChapter- 11: PATENT ANALYSISPATENTS BY YEARPATENTS BY TYPEPATENTS BY COUNTRYPATENTS BY COMPANYPATENTS BY ASSIGNEETable 109 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009Figure 55 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009Chapter- 12: COMPANY PROFILESABBOTT LABORATORIESABRAXIS BIOSCIENCE, INC.AKELA PHARMAAKORN, INC.ALCON, INC.ALEXION PHARMACEUTICALSALKERMES, INC.ALLERGANALPHARXAMGENANTIGENICSA P PHARMAASTELLAS PHARMAASTRAZENECAATON PHARMABARR PHARMACEUTICALS, INC.BAXTERBAYER HEALTHCAREBIOGEN IDECBIOSANTE PHARMACEUTICALS, INC.BIOVAILBOEHRINGER INGELHEIMBRISTOL MYERS SQUIBBCENTOCORCEPHALON INC.COLUMBIA LABSDIATOS SAEISAI CO.ELANENZONEURAND N.V.GENENTECHGENEREX BIOTECHGENZYME
  6. 6. GILEAD SCIENCES, INC.GLAXOSMITHKLINE PLCIMCLONE SYSTEMSJOHNSON AND JOHNSONKING PHARMACEUTICALSK.V. PHARMACEUTICAL CO.LAVIPHARM CORPORATION3M COMPANYMERCK & CO.MYLAN LABORATORIES, INC.NEKTAR THERAPEUTICSNOVEN PHARMACEUTICALS, INC.NOVARTIS AGNOVAVAX, INC.NYCOMED US, INC.OSI PHARMACEUTICALS, INC.PAR PHARMACEUTICAL COMPANIES, INC.PDL BIOPHARMA, INC.PFIZER INC.QLT, INC.ROCHESANOFI-AVENTISSCHERING-PLOUGHTEVA PHARMACEUTICAL INDUSTRIES, LTD.WATSON PHARMACEUTICALS, INC.WYETH, INC.ABBREVIATIONSList of TablesSummary Table : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014Table 1 : GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGESTable 2 : LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGESTable 3 : SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGESTable 4 : SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGESTable 5 : TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 6 : ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 7 : INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES ANDDISADVANTAGESTable 8 : RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 9 : NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 10 : VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 11 : OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 12 : PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGESTable 13 : SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGESTable 14 : DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGESTable 15 : PRODRUGS, ADVANTAGES AND DISADVANTAGESTable 16 : IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGESTable 17 : LIPOSOMES, ADVANTAGES AND DISADVANTAGESTable 18 : POLYMERS, ADVANTAGES AND DISADVANTAGES
  7. 7. Table 19 : MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGESTable 20 : PEGYLATION, ADVANTAGES AND DISADVANTAGESTable 21 : FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMSTable 22 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,2005- FEB. 2009Table 23 : APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIESTable 24 : RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMSTable 25 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORALDOSAGE FORMSTable 26 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLEDOSAGE FORMSTable 27 : MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICALDOSAGE FORMSTable 28 : MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGSTable 29 : MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDSTable 30 : MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERYSYSTEMSTable 31 : MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMESTable 32 : MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLESTable 33 : MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERSTable 34 : MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIESTable 35 : MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGYTable 36 : MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMSTable 37 : MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMSTable 38 : MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERYSYSTEMSTable 39 : MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERYSYSTEMSTable 40 : MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMSTable 41 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORALDOSAGE FORMS, 2008Table 42 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASEINJECTABLE DOSAGE FORMS, 2008Table 43 : SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICALDOSAGE FORMS, 2008Table 44 : SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008`Table 45 : SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008Table 46 : SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERYSYSTEMS, 2008Table 47 : SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008Table 48 : SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008Table 49 : SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008Table 50 : SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008Table 51 : SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008Table 52 : SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERYSYSTEMS, 2008Table 53 : SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERYSYSTEMS, 2008Table 54 : SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY
  8. 8. SYSTEMS, 2008Table 55 : SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERYSYSTEMS, 2008Table 56 : SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008Table 57 : DRUGS WHICH LOST THEIR PATENTS IN 2008Table 58 : DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009Table 59 : GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014Table 60 : MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008Table 61 : GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014Table 62 : GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,THROUGH 2014Table 63 : GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH2014Table 64 : TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014Table 65 : GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014Table 66 : GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014Table 67 : GLOBAL SALES OF LIPOSOMES, THROUGH 2014Table 68 : GLOBAL SALES OF NANOPARTICLES, THROUGH 2014Table 69 : GLOBAL SALES OF POLYMERS, THROUGH 2014Table 70 : GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014Table 71 : GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014Table 72 : GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014Table 73 : GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)Table 74 : GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014Table 75 : GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014Table 76 : GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014Table 77 : DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMSTable 78 : DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMSTable 79 : DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMSTable 80 : DEVELOPMENTS IN PRODRUGSTable 81 : DEVELOPMENTS IN IMPLANTS AND IUDSTable 82 : DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMSTable 83 : DEVELOPMENTS IN LIPOSOMAL DELIVERYTable 84 : DEVELOPMENTS IN PEGYLATED DRUG DELIVERYTable 85 : DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERYTable 86 : DEVELOPMENTS IN MONOCLONAL ANTIBODIESTable 87 : DEVELOPMENTS IN BUCCAL DRUG DELIVERYTable 88 : DEVELOPMENTS IN VAGINAL DRUG DELIVERYTable 89 : DEVELOPMENTS IN RECTAL DRUG DELIVERYTable 90 : DEVELOPMENTS IN INHALATION DRUG DELIVERYTable 91 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA,THROUGH 2014Table 92 : SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008Table 93 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,THROUGH 2004Table 94 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014Table 95 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINALDISORDERS, THROUGH 2014Table 96 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014
  9. 9. Table 97 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH2014Table 98 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEMMARKET, THROUGH 2014Table 99 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES,THROUGH 2014Table 100 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY ANDALLERGY, 2007-2014Table 101 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH2014Table 102 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIALDISEASES, THROUGH 2014Table 103 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENTTHERAPY AND GYNECOLOGY, THROUGH 2014Table 104 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREASAND TECHNOLOGIES, THROUGH 2014Table 105 : TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009Table 106 : NUMBER OF PATENTS BY TYPE, 2005-2009Table 107 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009Table 108 : NUMBER OF PATENTS BY COMPANY, 2005-2009Table 109 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009List of FiguresSummary Figure : GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014Figure 1 : NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,2005 TO FEB. 2009Figure 2 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORALDOSAGE FORMS, 2008Figure 3 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLEDOSAGE FORMS, 2008Figure 4 : SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICALDOSAGE FORMS, 2008Figure 5 : SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008Figure 6 : SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008Figure 7 : SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERYSYSTEMS, 2008Figure 8 : SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008Figure 9 : SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008Figure 10 : SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008Figure 11 : Shares of MANUFACTURERS/suppliers of monoclonal antibodies, 2008Figure 12 : SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008Figure 13 : SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERYSYSTEMS, 2008Figure 14 : SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERYSYSTEMS, 2008Figure 15 : SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERYSYSTEMS, 2008Figure 16 : SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERYSYSTEMS, 2008
  10. 10. Figure 17 : SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008Figure 18 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014Figure 19 : MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008Figure 20 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2007-2014Figure 21 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,2007-2014Figure 22 : TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS,2007-2014Figure 23 : GLOBAL SALES OF PRODRUGS, 2007-2014Figure 24 : TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014Figure 25 : TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2007-2014Figure 26 : TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014Figure 27 : GLOBAL SALES OF NANOPARTICLES, 2007-2014Figure 28 : GLOBAL SALES OF POLYMERS, 2007-2014Figure 29 : TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014Figure 30 : TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014Figure 31 : TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014Figure 32 : TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014Figure 33 : TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014Figure 34 : TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014Figure 35 : TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014Figure 36 : GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014Figure 37 : SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008Figure 38 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,2007-2014Figure 39 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014Figure 40 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINALDISORDERS, 2007-2014Figure 41 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014Figure 42 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, 2007-2014Figure 43 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEMMARKET, 2007-2014Figure 44 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES,2007-2014Figure 45 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGYDISEASES, 2007-2014Figure 46 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2007-2014Figure 47 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIALDISEASES, 2007-2014Figure 48 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENTTHERAPY AND GYNECOLOGY, 2007-2014Figure 49 : GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREASAND TECHNOLOGIES, 2007-2014Figure 50 : NUMBER OF PATENTS, 2005-2009Figure 51 : NUMBER OF PATENTS BY TYPE, 2005-2009Figure 52 : TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009Figure 53 : TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009
  11. 11. Figure 54 : NUMBER OF PATENTS BY COMPANY, 2005-2009Figure 55 : NUMBER OF PATENTS BY ASSIGNEE, 2005-2009Latest Market Research Reports: Global Market for Catalyst Regeneration Markets for Advanced Wound Care Technologies Wireless Sensors: Technologies and Global Markets Remote Sensing Technologies and Global Markets Portable Battery Powered Products: Global Markets Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets Embedded Systems: Technologies and MarketsAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Market Research Reports Blog

×